Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model
NCT ID: NCT01332188
Last Updated: 2017-08-30
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
101 participants
INTERVENTIONAL
2011-04-30
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
NCT01881113
Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model
NCT01134328
A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
NCT01685242
A Multi-Center Study Evaluating the Safety of AC-170 0.24%
NCT02132169
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.
NCT00770133
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AC-170 0.05%
AC-170 0.05%
1 drop in each eye at 3 separate times during a 21 day period
AC-170 0.1%
AC-170 0.1%
1 drop in each eye at 3 separate times during a 21 day period
AC-170 0.24%
AC-170 0.24%
1 drop in each eye at 3 separate times during a 21 day period
AC-170 0%
AC-170 0%
1 drop in each eye at 3 separate times during a 21 day period
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AC-170 0.05%
1 drop in each eye at 3 separate times during a 21 day period
AC-170 0.1%
1 drop in each eye at 3 separate times during a 21 day period
AC-170 0.24%
1 drop in each eye at 3 separate times during a 21 day period
AC-170 0%
1 drop in each eye at 3 separate times during a 21 day period
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters.
* Use of disallowed medications during the period indicated prior to the study enrollment or during the study.
10 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aciex Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gail L Torkildsen, MD
Role: PRINCIPAL_INVESTIGATOR
Andover Eye Associates
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ora, Inc.
Andover, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-100-0004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.